Josef Rickenbach - PAREXEL International Founder, Chairman and CEO

PRXL -- USA Stock  

USD 88.06  0.04  0.0454%

  Chairman
Mr. Josef H. von Rickenbach is Chairman of the Board, Chief Executive Officer of Parexel International Corporationrationration. Mr. von Rickenbach founded the Company in 1982 and has served as a director, Chairman of the Board and Chief Executive Officer of the Company since 1983. He also served as President from 1983 to April 2001 and from July 2005 to July 2012. Mr. von Rickenbach has also worked in the past for ScheringPlough, Inc., 3M, a division of 3M Company, and ERCO, Inc., a diversified testing and technical consulting company. He served as Chair of the Association of Clinical Research Organizations, a professional industry organization, in 2005 and 2013 and was a member of its Board of Directors for 12 years. He serves on the Board of Directors, and as Chair of the Nominating Committee, of NEHI
Age: 60  Chairman Since 2012  MBA    
781 487-9900  http://www.parexel.com
von Rickenbach received an M.B.A. from Harvard Business School and a B.A. in Business Economics from the Lucerne University of Applied Sciences and Arts in Switzerland.

Management Efficiency

The company has return on total asset (ROA) of 6.72 % which means that it generated profit of $6.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 16.93 % meaning that it created $16.93 on every $100 dollars invested by stockholders.
The company currently holds 671.5M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Found 9 records

CHAIRMAN Since

Joseph PapaPerrigo Company plc
2015
Roy VagelosRegeneron Pharmaceuticals
1995
Joshua BogerVertex Pharmaceuticals Incorpor
2009
Michael McCallisterZoetis
2015
Jeffrey LeidenVertex Pharmaceuticals Incorpor
2012
G PrasadDr Reddys Laboratories Limited
2014
Satish ReddyDr Reddys Laboratories Limited
2014
Marry BrlasPerrigo Company plc
2016
Weidong YinSinovac Biotech Ltd
2003

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corporation (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Did you try this?

Run Crypto Portfolio Optimizer Now

   

Crypto Portfolio Optimizer

Optimize portfolio of digital coins and token across multiple currency and exchanges
All  Next Launch Crypto Portfolio Optimizer
Currently Active Assets on Macroaxis
UBI   
Purchased over 40 shares of
2 days ago
Traded for 75.02
VMW   
Purchased few shares of
2 days ago
Traded for 181.56
F   
Purchased over 300 shares of
2 days ago
Traded for 8.43
F   
Purchased over 300 shares of
2 days ago
Traded for 8.43
CRM   
Purchased few shares of
2 days ago
Traded for 161.51
Additionally take a look at Your Equity Center. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.
Search macroaxis.com